Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：5

作者：

Packer, Milton ^{[1
,2
]}

Cleland, John G. F. ^{[3
]}

Bauersachs, Johann ^{[4
]}

机构：

[1] Baylor Heart & Vasc Inst, Dallas, TX USA

[2] Imperial Coll, London, England

[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland

[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany

来源：

EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期

关键词：

Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;

D O I：

10.1093/eurheartj/ehae300

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

引用

页码：2186 / 2196

页数：11

共 50 条

[41] SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure [J].

Ahmad, Tariq ;

Desai, Nihar R. ;

Velazquez, Eric J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (14) :1311-1313

[42] The Pleiotropic Effects of SGLT2 Inhibitors Remodeling the Treatment of Heart Failure [J].

Goldberg, Lee R. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (03) :256-258

[43] SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease? [J].

Echouffo-Tcheugui, Justin B. ;

Lewsey, Sabra C. ;

Weiss, Robert G. .

JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (23)

[44] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials [J].

Zannad, Faiez ;

Ferreira, Joao Pedro ;

Pocock, Stuart J. ;

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Brueckmann, Martina ;

Ofstad, Anne Pernille ;

Pfarr, Egon ;

Jamal, Waheed ;

Packer, Milton .

LANCET, 2020, 396 (10254) :819-829

[45] Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis [J].

Gager, Gloria M. M. ;

Gelbenegger, Georg ;

Jilma, Bernd ;

von Lewinski, Dirk ;

Sourij, Harald ;

Eyileten, Ceren ;

Filipiak, Krzysztof ;

Postula, Marek ;

Siller-Matula, Jolanta M. M. .

FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8

[46] Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction [J].

Mustapic, Ivona ;

Bakovic, Darija ;

Grabovac, Zora Susilovic ;

Borovac, Josip A. .

JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)

[47] Expanded use of sodium-glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction [J].

Schoenborn, Erika Michelle ;

Skersick, Preston Trudell ;

Thrasher, Claire Maxine ;

Page, Robert L. .

PHARMACOTHERAPY, 2023, 43 (09) :950-962

[48] SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study [J].

Lu, He ;

Shang, Pingping ;

Zhou, Dexing .

FRONTIERS IN PHARMACOLOGY, 2023, 14

[49] SGLT2 inhibitors and heart failure - clinical implications [J].

Raz, Itamar ;

Cahn, Avivit .

NATURE REVIEWS CARDIOLOGY, 2016, 13 (04) :185-186

[50] Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction [J].

Gonzalez, Jimmy ;

Bates, Benjamin A. ;

Setoguchi, Soko ;

Gerhard, Tobias ;

Dave, Chintan V. .

CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)

← 1 2 3 4 5 →